Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It is produced by Sorangium cellulosum. On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. In November 2008, the EMEA has refused a marketing authorisation for Ixabepilone. Ixabepilone is administered through injection, and is marketed under the trade name Ixempra.

June 21, 2017

prudect name : Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It is produced by Sorangium cellulosum. On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. In November 2008, the EMEA has refused a marketing authorisation for Ixabepilone. Ixabepilone is administered through injection, and is marketed under the trade name Ixempra.
Ixabepilone

Synonyms: BMS-247550 ;Azaepothilone B;BMS 247550-1CAS NO: 219989-84-1Molecular Formula: C₂₇H₄₂N₂O₅SMolecular Weight: 506.70Purity: 98% minSolubility: In DMSOStorage: -20°C

ACY1215 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18520029